Stock Analysis

At R$2.79, Is It Time To Put Iguatemi S.A. (BVMF:IGTI3) On Your Watch List?

BOVESPA:IGTI3
Source: Shutterstock

While Iguatemi S.A. (BVMF:IGTI3) might not be the most widely known stock at the moment, it led the BOVESPA gainers with a relatively large price hike in the past couple of weeks. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Let’s take a look at Iguatemi’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for Iguatemi

What's The Opportunity In Iguatemi?

Good news, investors! Iguatemi is still a bargain right now. According to my valuation, the intrinsic value for the stock is R$3.54, but it is currently trading at R$2.79 on the share market, meaning that there is still an opportunity to buy now. Although, there may be another chance to buy again in the future. This is because Iguatemi’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What kind of growth will Iguatemi generate?

earnings-and-revenue-growth
BOVESPA:IGTI3 Earnings and Revenue Growth September 18th 2022

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With revenues expected to grow by 33% over the next couple of years, the future seems bright for Iguatemi. If the level of expenses is able to be maintained, it looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? Since IGTI3 is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on IGTI3 for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy IGTI3. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. When we did our research, we found 2 warning signs for Iguatemi (1 shouldn't be ignored!) that we believe deserve your full attention.

If you are no longer interested in Iguatemi, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.